Title: Radioactive PTT as part of screening protocol for prospecting radiation workers
Authors: Alejandro Q. Nato, Jr., Sheila C. Sajise, and Custer C. Deocaris
Technical Report Institution: Philippine Nuclear Research Institute
Catalogued by: International Nuclear Information System
Publication Date: 2002
Volume: 33
Issue: 47
Technical Report Source: PNRI-C(NM)--02001
Technical Report Reference Number: 33064733
Abstract: Heterozygous mutations in BRCA1 or BRCA2 have been found to be associated with enhanced cellular radiosensitivity with impaired proliferative capacity after irradiation and could predispose increased risk of radiation-induced mutagenesis and carcinogenesis (1,2). Deficient repair mechanism exhibited by lymphocytes from breast cancer patients provides associated vulnerability to genotoxicity of ionizing radiation. Other genes may also play a role in terms of clinical radiation hypersensitivity needed in predicting response to radiotherapy. However, relaxation of cell cycle checkpoints, production of micronuclei, and loss of proliferative capacity which have been exhibited by impairment of irradiated cells lacking functional BRCA1 and BRCA2, accentuate the notion that heterozygous women may respond differently to radiation. The radioactive protein truncation test (PTT), utilized as screening procedure to detect frameshift mutations, can be employed to clarify radiosensitivity of individuals carrying a mutated BRCA1 gene. It can, therefore, be incorporated in the series of clinical assays used in standard screening protocols for prospective nuclear facility workers.
Citation PDF URL: http://www.iaea.org/inis/collection/NCLCollectionStore/_Public/33/064/33064733.pdf